Biote Holdings, a hormone therapy services provider, went public via a SPAC merger with Haymaker Acquisition III, a special purposes acquisition company, in a $737m deal. “Biote has a huge opportunity to enable physicians to help this highly underserved patient population take greater control of their health. Biote is committed to educating and empowering providers to effectively treat patients and help them understand the critical role that hormones play in healthy aging. We welcome Haymaker as partners and look forward to the role our status as a public company will play in increasing access to, and awareness of, our leading hormone therapy practice-building business," Terry Weber, Biote CEO.